Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.74 |
| ▸ | ACHE | P22303 | 3/20 | 0.74 |
| ▸ | APP | P05067 | 3/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.60 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.60 |
| ▸ | MAOB | P27338 | 6/20 | 0.57 |
| ▸ | KDM4A | O75164 | 2/20 | 0.53 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14376731 | 1.00 | BCHE (0.74) | BCHEACHEAPPHDAC3HDAC1 | |
| SCHEMBL14376859 | 1.00 | BCHE (0.74) | BCHEACHEAPPHDAC3HDAC1 | |
| SCHEMBL14376730 | 0.98 | BCHE (0.72) | BCHEACHEAPPHDAC3HDAC1 | |
| SCHEMBL10468744 | 0.94 | BCHE (0.65) | BCHEACHEAPPHDAC3HDAC1 | |
| SCHEMBL25181480 | 0.90 | HDAC1 (0.67) | BCHEACHEAPPHDAC3HDAC1 | |
| SCHEMBL15456409 | 0.90 | HDAC1 (0.71) | BCHEACHEAPPHDAC3HDAC1 | |
| SCHEMBL25180614 | 0.90 | HDAC1 (0.67) | BCHEACHEAPPHDAC3HDAC1 | |
| SCHEMBL4327317 | 0.89 | HDAC1 (0.71) | BCHEACHEAPPHDAC3HDAC1 | |
| SCHEMBL11682230 | 0.87 | BCHE (0.60) | BCHEACHEAPPHDAC3HDAC1 | |
| SCHEMBL9126033 | 0.86 | BCHE (0.57) | BCHEACHEAPPHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | SB PHARMCO PUERTO RICO INC. AND NEUROCRINE BIOSCIENCES, INC., A CORPORATION | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | CRHR1, CRHR2, CRH | BCHE 851/4885ACHE 2657/4885APP 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.